3.86 (-%)
As of Dec 06, 2024
Source:
Curis Inc is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4.
Country | United States |
Headquarters | lexington, massachusetts |
Phone Number | 617-503-6500 |
Industry | manufacturing |
CEO | James E. Dentzer |
Website | www.curis.com |